Halobetasol and Tazarotene and Insulin glargine and lixisenatide Subcutaneous
Determining the interaction of Halobetasol and Tazarotene and Insulin glargine and lixisenatide Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: halobetasol / tazarotene topical
Brand name: Duobrii
Synonyms: Halobetasol and tazarotene topical
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Halobetasol and Tazarotene-Insulin glargine, recombinant Subcutaneous
- Halobetasol and Tazarotene-Insulin glulisine
- Halobetasol and Tazarotene-Insulin Glulisine (Cartridges and Pens)
- Halobetasol and Tazarotene-Insulin Glulisine (Vials)
- Halobetasol and Tazarotene-Insulin glulisine Subcutaneous
- Halobetasol and Tazarotene-Insulin human inhaled Inhalation
- Insulin glargine and lixisenatide Subcutaneous-Halobetasol and tazarotene topical
- Insulin glargine and lixisenatide Subcutaneous-Halobetasol Cream
- Insulin glargine and lixisenatide Subcutaneous-Halobetasol Cream and Ointment
- Insulin glargine and lixisenatide Subcutaneous-Halobetasol Cream and Ointment with Lactic Acid Cream
- Insulin glargine and lixisenatide Subcutaneous-Halobetasol Foam
- Insulin glargine and lixisenatide Subcutaneous-Halobetasol Lotion